Scilex Holding Co (FRA:D8B0) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:D8B0 Scilex Holding Co FRA:D8B0
39 GF Score
Price €6.40
GF Value €4.77
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co FFO per Share?

FFO per Share only applies to REITs.

FRA:D8B0
39GF Score
Scilex Holding Co FRA:D8B0
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Scilex Holding Co (FRA:D8B0) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of €6.40 is trading 34.2% above its estimated GF Value™ of €4.77. GuruFocus considers Scilex Holding Co to be Significantly Overvalued.

Key valuation signals for FRA:D8B0:

  • FFO per Share:
  • GF Value™: €4.77 vs. price of €6.40 (34.2% above fair value)
  • GF Score™: 39/100 with 7 warning signs

No single metric tells the full story. See the FRA:D8B0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scilex Holding Co Business Description

Other Exchanges SCLX:USA
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
39GF Score

Get the complete analysis for FRA:D8B0

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.40
Price
€4.77
GF Value